企业特殊行业经营资质信息公示
<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">已经成为药剂学研发中非常常用的一种药用高分子材料，其优越性已被越来越多地认识，使它成为一种成熟
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的多用途药用辅料。<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">是由<***N style="FONT-SIZE: 9pt" lang=EN-US>N-<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">**基<***N style="FONT-SIZE: 9pt" lang=EN-US>-2-<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">吡喏烷酮单体催化生成的水溶性聚合物，极易吸湿结块，易溶于水和乙
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">醇等极性有机溶剂是其应用特点之一。药用聚维酮分子量在<***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">万<***N style="FONT-SIZE: 9pt" lang=EN-US>-70<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">万之间，一般以<***N style="FONT-SIZE: 9pt" lang=EN-US>K<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">之大小表示，<***N style="FONT-SIZE: 9pt" lang=EN-US>K<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">越大，分子
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">量越高如下表。<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">有许多优良的性质，其在药剂学中应用也越来越广泛，适用面越来越多，下面就对其在国内
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">在药物制剂开发研究中应用的主要方面做一下总结。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">规<***N style="FONT-SIZE: 9pt"> <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">格<***N style="FONT-SIZE: 9pt" lang=EN-US> (<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">分子量<***N style="FONT-SIZE: 9pt" lang=EN-US>MW)
<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK15 (8,000)
<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK25 (30,000)
<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK30 (50,000)
<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK60 (400,000)
<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK90 (1,000,000)
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">无热源<***N style="FONT-SIZE: 9pt" lang=EN-US>C<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">级<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK120 (3,000,000)
<***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、口服固体制剂的粘合剂<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">在水中和一些常使用的有机溶剂中可溶，使它在许多情况下都能使用。首先，在对湿、热敏感的药剂，
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">用<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的乙醇溶液做粘合剂可以消除水热等因素的影响，而对疏水性药物，采用其水溶液可以均匀润湿，而且
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">可以药物颗粒表面具有亲水性有利于增加药物的溶出度。此外，<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">做粘合剂可以干粉加入，在以适当溶剂润
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">湿制粒或做干粘合剂直接压片可以改善疏水性药物的脱片现象。常用<***N style="FONT-SIZE: 9pt" lang=EN-US>K30<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">和<***N style="FONT-SIZE: 9pt" lang=EN-US>K25<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">，<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK30<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的用量一般在<***N style="FONT-SIZE: 9pt" lang=EN-US>2%--5%<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">在泡腾剂中的使用，<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">是比较理想的粘合剂，因为泡腾剂要求严格控制水分含量，用<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的乙醇溶液做粘合剂
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">就能很好地解决这个问题。由此做成的泡腾片颗粒可厌性好，溶解迅速，并可强烈发泡。用约<***N style="FONT-SIZE: 9pt" lang=EN-US>5%--10%<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">液做粘合剂还可用于流化床喷雾干燥制粒。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">将双氯芬酸钠与淀粉、乳糖等混合，用<***N style="FONT-SIZE: 9pt" lang=EN-US>DQD <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">乙醇溶液搅拌制粒得速释颗粒。取部分速释颗粒继用乙基纤维素的
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">乙醇，**溶液包衣得缓释颗粒，上述两种颗粒按<***N style="FONT-SIZE: 9pt" lang=EN-US>7 K 5 <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">混合后装胶囊即得。另报道胃漂浮型缓释胶囊，显示良
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">好的释药性能。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-SIZE: 9pt" lang=EN-US>2<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、用在口服液体制剂中增稠、增粘<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">在口服液体制剂中作为增稠剂的历史已经比较长了而且有了广泛的应用，比如其在乳剂和混悬剂<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK-90
<***N style="FONT-SIZE: 9pt" lang=EN-US><***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">就可作为很好的增稠稳定剂，而且聚合物是被吸附在单个胶体离子表面上形成了一薄层分子层以防止其聚结。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">进行*****透皮给药系统研究中，在药库制备过程中就加入了<***N style="FONT-SIZE: 9pt" lang=EN-US>50%<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的<***N style="FONT-SIZE: 9pt" lang=EN-US>pvp<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">，结果证明<***N style="FONT-SIZE: 9pt" lang=EN-US>pvp<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">与<***N style="FONT-SIZE: 9pt" lang=EN-US>PVA<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">及甘油的比
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">例是影响药库性能的主要因素，而且如不加<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">药库容易干燥变硬。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">左旋氧氟沙星是目前公认的疗效显著的眼科<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">高声传<***N style="FONT-SIZE: 9pt" lang=EN-US>[3]<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">为此研制左旋氧氟沙星滴眼剂抗菌药。以聚*****酮
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>(PVP) <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">为增粘剂<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">制备的左旋氧氟沙星缓释滴眼缓释剂<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">滴入眼内后可在眼球表面形成一层较薄的膜<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">不会像普通滴
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">眼剂那样药液会大部分流失<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">从而使药物在眼部维持相对较长的治疗时间<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">疗效加强；而且<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶液具有一定的粘
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">度<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">流动性小<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">且透明性好<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">不影响视线<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">比现有的油性眼膏更具优越性。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">有文献<***N style="FONT-SIZE: 9pt" lang=EN-US>[4]<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">报道<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">加入纤维素多聚物可延长药物与鼻粘膜接触时间<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">从而提高药物的疗效。杨建红<***N style="FONT-SIZE: 9pt" lang=EN-US>[5]<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">等在对维生素
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>B12<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">滴鼻剂的鼻粘膜纤毛毒性评价研究中，加了<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">做增稠剂<***N style="FONT-SIZE: 9pt" lang=EN-US> 1% PV P <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶液对**上腭纤毛运动基本无影响，
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">纤毛运动相对抑制百分率均在<***N style="FONT-SIZE: 9pt" lang=EN-US>90% <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">以上。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-SIZE: 9pt" lang=EN-US>3<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、用作固体分散体载体载体<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">提高难溶性药物的体内吸收一直是一个热门的课题，要达到此目的，考虑提高其溶解度和溶解速度，固体分散体
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">就是将难溶性药物以分子、胶态、微晶或无定型态分散在一种水溶性材料中而成，能显著提高溶出速率而更以吸
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">收。<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">就是植被固体分散体常用的载体。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">杨建彬<***N style="FONT-SIZE: 9pt" lang=EN-US>[6]<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">制备****固体分散体通过比较研究<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">确定****各种比例固体分散体的溶出速率与药物原粉间均
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">有显著性差异<***N style="FONT-SIZE: 9pt" lang=EN-US>( P < 0. 05) <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">或极显著性差异<***N style="FONT-SIZE: 9pt" lang=EN-US>( P < 0. 001) , <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶出速率明显大于药物原粉<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">且<***N style="FONT-SIZE: 9pt" lang=EN-US>Car - PEG- 6000 <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">和
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>Car - PVP <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">两种固体分散物都显示了同一结果<***N style="FONT-SIZE: 9pt" lang=EN-US>:<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">随着载体量的增大<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶出加快<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">但随着载体量的增加<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶出速度的增
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">加趋缓。<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">作为****的载体溶出效果好于<***N style="FONT-SIZE: 9pt" lang=EN-US>PEG- 6000 , <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">且在另一老化试验中<***N style="FONT-SIZE: 9pt" lang=EN-US>, Car - PEG- 6000 <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">较<***N style="FONT-SIZE: 9pt" lang=EN-US>Car -
<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">易老化<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">因此笔者认为<***N style="FONT-SIZE: 9pt" lang=EN-US>,PVP <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">作为****的固体分散体载体更优。<***N style="FONT-SIZE: 9pt" lang=EN-US>PEG - 6000 <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">都是常用的固体分散
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">体载体<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">基本上都不会干扰主药的测定。<***N style="FONT-SIZE: 9pt"> <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">****经固体分散技术处理后<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">能显著提高体外溶出速率<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">进而提高体
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">内生物利用度，为****制成**制剂提供了一有效途径。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">马来酸罗格列酮在肠液中溶解度较小<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">推测其在肠道的吸收速率将会因此而受到影响<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">所以有必要将马来酸罗格列
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">酮制成固体分散体<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">以增加其溶解度和溶出速率。红外光谱分析证明二者并未发生化学反应，<***N style="FONT-SIZE: 9pt" lang=EN-US>X-<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">射线粉末衍射分
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">析说明其是以无定型状态分散于载体<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK30 <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">中的。以水溶性材料为载体<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">可通过提高药物的可润湿性、保证药
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">物的高度分散性和载体材料对药物的抑晶性而大大改善药物的溶出与吸收。作者分别制备了<***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-bidi-font-family: 宋体">∶<***N style="FONT-SIZE: 9pt" lang=EN-US>5<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、<***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-bidi-font-family: 宋体">∶<***N style="FONT-SIZE: 9pt" lang=EN-US>10<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、<***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-bidi-font-family: 宋体">∶<***N style="FONT-SIZE: 9pt" lang=EN-US>15<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-bidi-font-family: 宋体">∶<***N style="FONT-SIZE: 9pt" lang=EN-US>20(<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">药物<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-bidi-font-family: 宋体">∶<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP K30) <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的固体分散体<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶出速率没有显著性差异<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">考虑到辅料用量<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">选择<***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-bidi-font-family: 宋体">∶<***N style="FONT-SIZE: 9pt" lang=EN-US>5 <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的固体分散体<***N style="FONT-SIZE: 9pt" lang=EN-US>[7]<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-SIZE: 9pt" lang=EN-US>4<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、用作薄膜包衣材料<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">通常用规格的<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">因其柔韧性较理想，可作为药用成膜材料或与其它膜材合用。实践已经证明<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">能用于水和
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">有机溶剂两种系统的薄膜包衣工艺，其包衣的优点：能改善膜对表面的粘附能力，改善色淀或染料的分散性，
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">可作为薄膜增塑剂，可改变以疏水材料为基料的薄膜的崩解时间。包衣时的常用浓度为<***N style="FONT-SIZE: 9pt" lang=EN-US>0.5%---5%<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">。目前已有
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>PVP/VA<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">系列产品专门用作成膜材料，它们是<***N style="FONT-SIZE: 9pt" lang=EN-US>VP(<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">**吡喏烷酮<***N style="FONT-SIZE: 9pt" lang=EN-US>)<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">与<***N style="FONT-SIZE: 9pt" lang=EN-US>VA(<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">乙酸**酯<***N style="FONT-SIZE: 9pt" lang=EN-US>)<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的共聚物。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-SIZE: 9pt" lang=EN-US>5<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、用在缓控释制剂中<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">在缓控释制剂中<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">可以做粘合剂，阻滞剂，促渗剂等。叶琳琳<***N style="FONT-SIZE: 9pt" lang=EN-US>[8]<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">等研制了单室单层硝苯地平口服渗透泵片<***N style="FONT-SIZE: 9pt" lang=EN-US>,
<***N style="FONT-SIZE: 9pt" lang=EN-US><***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">对硝苯地平口服渗透泵片的配方和制备参数进行优化<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">所确定的**片芯配方，其中<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">作为助渗剂含量为
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>7.08%<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">。结果表明<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">作者制备的硝苯地平渗透泵片的体外释放较好地符合渗透泵零级释药特征。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-SIZE: 9pt" lang=EN-US>6<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP-I(<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">聚维酮碘制剂<***N style="FONT-SIZE: 9pt" lang=EN-US>)
<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP-I(<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">聚维酮碘制剂<***N style="FONT-SIZE: 9pt" lang=EN-US>)[9]<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">是碘与<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">形成的一种可溶性复合物，是一种**、光谱新型杀菌剂，与碘相比具有挥
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">发性小、水溶性好、几乎无刺激性、过敏性等优点。目前已有许多产品在研或已经上市，包括了多种剂型溶液
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">剂（皮肤用消毒剂和眼科用消毒剂）、栓剂（阴道栓、尿道栓及泡腾栓<***N style="FONT-SIZE: 9pt" lang=EN-US>[10]<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">）、软膏剂及涂剂。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-SIZE: 9pt" lang=EN-US>7<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、交联<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP(CPVP )<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的应用<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">分散片是近年来才开发的新剂型<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">日益受到重视。国外已上市的分散片品种有<***N style="FONT-SIZE: 9pt" lang=EN-US>10 <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">多个<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">国内至今已批准分散片<***N style="FONT-SIZE: 9pt" lang=EN-US>28
<***N style="FONT-SIZE: 9pt" lang=EN-US> <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">种<***N style="FONT-SIZE: 9pt" lang=EN-US>(<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">同期只批泡腾片<***N style="FONT-SIZE: 9pt" lang=EN-US>11 <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">种<***N style="FONT-SIZE: 9pt" lang=EN-US>) <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">但其中只有中药品种<***N style="FONT-SIZE: 9pt" lang=EN-US>1 <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">个。分散片的崩解剂一般需要加入**崩解剂，常用的有
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>CPVP,L-HPC,CMS-Na<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">等。李瑞明<***N style="FONT-SIZE: 9pt" lang=EN-US>[11]<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">在进行感冒灵分散片的研制中就以<***N style="FONT-SIZE: 9pt" lang=EN-US>CPVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">为崩解剂可知<***N style="FONT-SIZE: 9pt" lang=EN-US>MCC<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">与交联<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP
<***N style="FONT-SIZE: 9pt" lang=EN-US><***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">联用的崩解效果较佳<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">可能是因为道他们有协同作用。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-SIZE: 9pt" lang=EN-US>8<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、其它应用<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>
<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">还可用在新型的药物释放系统中，比如张学农<***N style="FONT-SIZE: 9pt" lang=EN-US>[12]<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">阿苯达唑聚氰基******纳米粒的制备、性质及其组
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">织靶向性研究时，在纳米粒制备的溶液中加入<***N style="FONT-SIZE: 9pt" lang=EN-US>4 %PVP <***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">可增大溶液粘度<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">提高载体的吸附性<***N style="FONT-SIZE: 9pt" lang=EN-US> ,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">其体外释药呈双指数
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">函数<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">有<***N style="FONT-SIZE: 9pt" lang=EN-US>"<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">爆破<***N style="FONT-SIZE: 9pt" lang=EN-US>"<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">释药特点<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">同时可提高纳米粒的物理稳定性。此外，在注射剂的开发中，注射用<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP 12PF<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的用作增
<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶剂（在一些品种中药物的溶解度明显被<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋体; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">提高）或抑晶剂应用也越来越多。<***N style="FONT-SIZE: 9pt" lang=EN-US>
<***N style="FONT-SIZE: 9pt" lang=EN-US>
